Navigation Links
ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
Date:1/5/2011

excluding any mark-to-market adjustments relating to warrants.
  • Year-end 2011 cash balance will be at least $90 million. This amount is after any debt repayments and includes reserves for XIBROM™/BROMDAY™ royalties.  

    • Ms. Silvernail said the company expects 2011 to be ISTA's second year of profitability, but due to timing of revenues and expenses, anticipates a loss in the first quarter of 2011, before warrant expense. She also noted that one-third of the company's $65 million debt facility comes due in September of 2011. The company anticipates making the $21 million principal repayment out of cash on hand, which was in excess of $75 million at the end of 2010.

    Commercial Update and Milestones for 2011

    During the commercial update, Dr. Anido said, "The launch of once-daily BROMDAY is going according to plan.  After only a few weeks on the market, BROMDAY has captured 6.5% of the new prescriptions in the non-steroidal anti-inflammatory eye care market and already represents 23% of new prescriptions for the XIBROM/BROMDAY franchise.  After BROMDAY is established, we plan to discontinue XIBROM and focus our sales force on promoting BEPREVE®, our prescription drop for ocular itching associated with allergic conjunctivitis, just in time for the spring allergy season."

    During the webcast/conference call, Dr. Anido outlined key pipeline milestones for 2011, including:

    • Initiating Phase 3 clinical trials for low-concentration BROMDAY for the treatment of postoperative inflammation and reduction of ocular pain post-cataract extraction – First Half
    • Publishing data in a medical journal on use of bromfenac with Lucentis* for age-related macular degeneration (AMD) – First Half
    • Announcing preliminary Phase 2 Mountain Cedar Pollen results for bepotastine nasal spray - First Half
    • Announcing preliminary Phase 3 efficacy
      '/>"/>

    SOURCE ISTA Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... , May 24, 2013  An international roster ... Saturday, May 18, in Santa Monica, Calif. ... new lung-sparing therapies for MPM, a rare form of ... affects the pleura, the lining of the chest. ... and Blood Institute, the 3rd Annual International Symposium on ...
    (Date:5/24/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that Dr. Robert Grieve , the ... Napolitano , executive vice president and chief financial officer, ... is being held May 30, 2013 in New ... The Company,s presentation is scheduled to begin at ...
    (Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
    Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4
    (Date:5/24/2013)... Chronic Fatigue Syndrome has been a mysterious ... fatigue lasting 6 months or longer. Symptoms of Chronic ... impairment, muscle and joint pain without swelling or redness, ... malaise that lasts for more than 24 hours. ... linked to insulin resistance. At a healthy body weight, ...
    (Date:5/24/2013)... Today marks the launch of Destination Halifax’s latest ... The redesigned and enhanced Itinerary Builder will help visitors ... computer or mobile device that they can send, save, ... to fill in their date of arrival and length ... of vacation packages, accommodations, restaurants, and things to do ...
    (Date:5/24/2013)... May 24, 2013 Bridal Buy ... to announce new 2013 bridesmaid dresses are ... bridesmaid dresses are handcrafted, featured as fine fabrics, elegant ... dress takes great skill and an eye for detailed ... hand-made embroidery, brought to life from patterns and the ...
    (Date:5/24/2013)... The leading retail brand Short Dresses ... short prom dresses . Now that is quite unbelievable, especially ... the brand name since its origin. The retailer has already ... now this huge discount offer will be an added bonanza ... highly privileged to announce that Short Dresses is to offer ...
    (Date:5/23/2013)... FL (PRWEB) May 24, 2013 ... the Cellulite Whisperer line, with a ... for Summer Sale" includes two proprietary products, the ... Whisperer® Lotion . , Purchasers receive a report ... , "The Gel has a wonderful grapefruit scent," ...
    Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2
    ... study conducted by researchers say it is a misconception ... older or housebound people.// ,Researchers examined 150 ... levels of vitamin D. Among the participants, all African-American, ... D deficiencies, as were all patients younger than 30. ...
    ... A pitch-black room may be the healthiest environment for your ... at night // may put children at risk for ... to disrupt the circadian rhythm and suppress the production of ... been shown to protect DNA from oxidative damage. Once damaged, ...
    ... study shows sinusitis in asthma patients tends to be ... suggest patients // can have dramatic improvement in symptoms ... is used. ,In the study patients with asthma ... polyps, olfactory dysfunction, and nasal congestion compared to patients ...
    ... new study shows moderate consumption of alcohol may cut ... arteries.// Researchers evaluated 225 men after they had undergone ... open blocked arteries with a stent. Less traumatic than ... cause inflammation resulting in renarrowing of the artery, usually ...
    ... study researchers say the antidepressant duloxetine, also known ... fibromyalgia in women . Duloxetine works by stopping ... of the brain’s neurotransmitters that are linked to ... that is characterized by body pain, muscle tenderness, ...
    ... cluster of risk factors known as metabolic syndrome is ... risk factors. // ,Metabolic syndrome has been ... coronary heart disease. Metabolic syndrome includes looking at factors ... has two different definitions including one by the National ...
    Cached Medicine News:
    Modified Freer periosteal elevator, #163, slight curve, 21 cm....
    Cottle periosteal & skin elevator, 7 1/2", slightly curved blade, 9 mm wide....
    Steinhauser periosteal elevator....
    Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
    Medicine Products: